IL-17A plays a significant role in PDAC by assisting in the early stages of cancer development [87, 88], controlling the characteristics of PDAC cancer stem cells (CSCs) [89], advancing tumor growth [83, 88, 90], and causing resistance to checkpoint inhibitors through the formation of NETs [91]. The gene discussed is IL17A; the disease is cancer.